College of Veterinary Medicine (BK21 Plus Project Team), Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju 61186, Republic of Korea.
Natural Product Research Center, Jeonbuk Branch, Korea Research Institute of Biosciences and Biotechnology, Ipsingil 181, Jeongeup, Jeollabuk-do 56212, Republic of Korea.
Int Immunopharmacol. 2019 Mar;68:124-130. doi: 10.1016/j.intimp.2019.01.001. Epub 2019 Jan 9.
S-Allyl cysteine (SAC) is an active component in garlic and has various pharmacological effects, such as anti-inflammatory, anti-oxidant, and anti-cancer activities. In this study, we explored the suppressive effects of SAC on allergic airway inflammation induced in an ovalbumin (OVA)-induced asthma mouse model. To induce asthma, BALB/c mice were sensitized to OVA on days 0 and 14 by intraperitoneal injection and exposed to OVA from days 21 to 23 using a nebulizer. SAC was administered to mice by oral gavage at a dose of 10 or 20 mg/kg from days 18 to 23. SAC significantly reduced airway hyperresponsiveness, inflammatory cell counts, and Th2 type cytokines in bronchoalveolar lavage fluid induced by OVA exposure, which was accompanied by reduced serum OVA-specific immunoglobulin E. In histological analysis of the lung tissue, administration of SAC reduced inflammatory cell accumulation into lung tissue and mucus production in airway goblet cells induced by OVA exposure. Additionally, SAC significantly decreased MUC5AC expression and nuclear factor-κB phosphorylation induced by OVA exposure. In summary, SAC effectively suppressed allergic airway inflammation and mucus production in OVA-challenged asthmatic mice. Therefore, SAC shows potential for use in treating allergic asthma.
S-烯丙基半胱氨酸(SAC)是大蒜中的一种活性成分,具有多种药理作用,如抗炎、抗氧化和抗癌活性。在这项研究中,我们探讨了 SAC 对卵清蛋白(OVA)诱导的哮喘小鼠模型中过敏性气道炎症的抑制作用。为了诱导哮喘,BALB/c 小鼠在第 0 天和第 14 天通过腹腔注射对 OVA 进行致敏,并在第 21 天至第 23 天通过雾化器暴露于 OVA。从第 18 天到第 23 天,SAC 通过口服灌胃以 10 或 20mg/kg 的剂量给予小鼠。SAC 显著降低了 OVA 暴露引起的气道高反应性、炎症细胞计数和支气管肺泡灌洗液中的 Th2 型细胞因子,同时降低了血清 OVA 特异性免疫球蛋白 E。在肺组织的组织学分析中,SAC 给药减少了 OVA 暴露引起的肺部炎症细胞积聚和气道杯状细胞中的粘液产生。此外,SAC 显著降低了 OVA 暴露诱导的 MUC5AC 表达和核因子-κB 磷酸化。总之,SAC 有效抑制了 OVA 挑战的哮喘小鼠中的过敏性气道炎症和粘液产生。因此,SAC 显示出在治疗过敏性哮喘方面的潜力。
Int Immunopharmacol. 2013-7-13
Int Immunopharmacol. 2019-9-4
Int Immunopharmacol. 2011-11-12
Clin Exp Pharmacol Physiol. 2007-8
Animals (Basel). 2022-9-19
Evid Based Complement Alternat Med. 2021-9-11
Front Immunol. 2021-5-20
Exp Ther Med. 2020-2